(AKBA) Akebia Ther - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00972D1054
AKBA: Kidney disease treatments, Anemia therapies, Iron deficiency medications
Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for patients with kidney diseases. The companys lead investigational product, Vafseo (vadadustat), is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor currently in Phase III trials for treating anemia associated with chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis patients. Akebia also markets Auryxia, a ferric citrate indicated for controlling serum phosphorus levels in dialysis-dependent CKD patients and treating iron deficiency anemia in non-dialysis CKD patients. The companys pipeline includes AKB-9090, a compound targeting critical-care indications, and AKB-10108, which focuses on conditions related to premature birth. Collaborations include a partnership with Mitsubishi Tanabe Pharma Corporation for vadadustat development and commercialization in Japan and other Asian markets, as well as a research and license agreement with Janssen Pharmaceutica NV for hypoxia-inducible factor prolyl hydroxylase-targeted therapies worldwide. Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia is committed to advancing treatments for kidney disease and related conditions. Web URL: https://www.akebia.com
3-Month Forecast: Based on the technical and fundamental data, Akebia Therapeutics (AKBA) is expected to face headwinds in the near term. The stock is trading below its SMA 20 and SMA 50, indicating bearish momentum. The high price-to-book ratio of 4.12 suggests elevated valuations relative to book value, which could limit upside potential. However, the positive return on equity (RoE) of 91.25% indicates efficient profitability from equity. The stock may experience volatility within a narrow range, bounded by the identified support level of 1.4. A potential stabilization or recovery could occur if the company reports positive clinical trial data or strengthens its pipeline.
Additional Sources for AKBA Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AKBA Stock Overview
Market Cap in USD | 369m |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2014-03-20 |
AKBA Stock Ratings
Growth 5y | -33.8% |
Fundamental | 5.96% |
Dividend | 0.0% |
Rel. Strength Industry | 78.6 |
Analysts | 4.33/5 |
Fair Price Momentum | 1.80 USD |
Fair Price DCF | - |
AKBA Dividends
No Dividends PaidAKBA Growth Ratios
Growth Correlation 3m | 9.8% |
Growth Correlation 12m | 62.1% |
Growth Correlation 5y | -58.9% |
CAGR 5y | -14.76% |
CAGR/Max DD 5y | -0.15 |
Sharpe Ratio 12m | -0.05 |
Alpha | 44.88 |
Beta | 2.44 |
Volatility | 68.86% |
Current Volume | 13249.9k |
Average Volume 20d | 2392.7k |
As of March 16, 2025, the stock is trading at USD 2.26 with a total of 13,249,864 shares traded.
Over the past week, the price has changed by +18.95%, over one month by +6.10%, over three months by +22.83% and over the past year by +64.96%.
Neither. Based on ValueRay Fundamental Analyses, Akebia Ther is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 5.96 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AKBA as of March 2025 is 1.80. This means that AKBA is currently overvalued and has a potential downside of -20.35%.
Akebia Ther has received a consensus analysts rating of 4.33. Therefor, it is recommend to buy AKBA.
- Strong Buy: 1
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AKBA Akebia Ther will be worth about 2.2 in March 2026. The stock is currently trading at 2.26. This means that the stock has a potential downside of -4.42%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 7.8 | 246.5% |
Analysts Target Price | 5.5 | 143.4% |
ValueRay Target Price | 2.2 | -4.4% |